U.S. Food and Drug Administration
Topic Paragraphs
Featured Topics
FDA.gov Website Refresh
FDA is pleased to announce the launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Recent Press Announcements
Jun 14
Federal officials seize adulterated dietary supplements from Life Rising Corporation due to poor manufacturing practices
Jun 11
FDA finalizes guidance for premarket tobacco product applications for electronic nicotine delivery systems as part of commitment to continuing a strong oversight of e-cigarettes
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Jun 14
In Cooperation with ADM Milling Co., Hometown Food Company Issues Voluntary Recall of Specific Lot Codes Pillsbury® Best Bread Flour Due to Possible Health Risk
Food & Beverages
Jun 14
Shivam Distributors Recalls “Dry Dates” Because of Possible Health Risk
Food & Beverages
Jun 14
Frito-Lay Issues Voluntary Allergy Alert on Undeclared Milk in Lay’s Lightly Salted Barbecue Flavored Potato Chips
Food & Beverages
FDA Voices: Perspectives from FDA Experts
FDA is Committed to Sound, Science-based Policy on CBD
FDA recognizes the significant public interest in products containing cannabis or cannabis-derived compounds, including CBD.
Supporting More Timely Development of Biologics for Patients
A robust market for safe, effective biosimilar products is crucial – more products on the market can lead to more access and reduced health care costs.
2019 Spring Unified Agenda Reflects FDA’s Continuity and Consistency
These regulatory actions are designed to advance the FDA’s policy priorities, innovation, and science-based decision-making.
Recently Published Guidances
Jun 13
Testing for Biotin Interference in In Vitro Diagnostic Devices
Biologics
Jun 13
Mouse Embryo Assay for Assisted Reproduction Technology Devices
Medical Devices
Jun 13
Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Drugs